Neovasc to Report Second Quarter Financial Results on August 11, 2022

Rhea-AI Summary

Neovasc Inc. (NVCN) will announce financial results for Q2 2022 on August 11, 2022. CEO Fred Colen and CFO Chris Clark will host a conference call at 4:30 PM EDT to discuss the outcomes. The company develops innovative cardiovascular products, including Reducer and Tiara™, with ongoing clinical investigations in the U.S. and internationally. These developments align with the growing cardiovascular market, presenting opportunities for Neovasc's product offerings.

Positive

• Upcoming financial results report could provide insights into company's performance.
• Focus on innovative cardiovascular products aligns with market growth.

Negative

• None.

VANCOUVER and MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ ,  TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on August 11, 2022.

Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13730925. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at  neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words expect, anticipate, estimate, may, will, should, intend, believe, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the Risk Factors section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three months ended March 31, 2022 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Email: Sean.Leous@icrinc.com

FAQ

When will Neovasc announce its Q2 2022 financial results?

Neovasc will announce its Q2 2022 financial results on August 11, 2022.

Who will host the Neovasc Q2 2022 earnings call?

The Q2 2022 earnings call will be hosted by CEO Fred Colen and CFO Chris Clark.

What products does Neovasc provide for cardiovascular treatment?

Neovasc offers products like Reducer and Tiara™, targeting cardiovascular diseases.

Is Neovasc's Reducer product available in the U.S.?

The Reducer is under clinical investigation in the U.S. but is available commercially in Europe since 2015.